Susavion Biosciences, Inc. designs peptide drugs that activate cellular assault processes against pathogens (i.e., antibody-dependent cellular cytotoxicity by natural killer cells and antibody-mediated phagocytosis by monocytes/macrophages/dendritic cells). The fundamental functions of these processes provide a general, rather than disease-specific, therapy.
Major diseases such as HIV and cancer suppress the immune system, which allows progression of the disease. A new approach to therapy, applicable to HIV and other diseases, is needed to reverse the immune escape of these diseases. Susavion Bioscience, Inc., developed a robust platform to identify activators of the immune system to treat chronic diseases. This technology is designed to boost efficacy of endogenously produced polyclonal or exogenously administered monoclonal antibodies and is applicable to immunosuppressive diseases such as infections of HIV and cancer. The arena in which Susavion operates is bounded by initial drug discovery and validation of peptides as functional drugs through the pre-clinical stage to Investigative New Drug approval.